Hepatitis Foundation International Cultivating a community that helps people with Hepatitis concerns manage and fulfill their lives
The Good We Do Living with Hepatitis News & Research Support Education Donate Contact Us
spacer
NNAC Online Learning Center Subscribe to Our Newsletter Parents
 
 

photoWe offer living and learning resources, support and answers.

palette

Foundation for Decision Making, Liver Wellness and Prevention of Hepatitis and Drug Abuse

Learn new techniques to protect yourself, your staff and your patients. We can train your staff, healthcare providers, and educators.

Call 1-800-891-0707
for information.




Join our cause!



NNAC

 
National Nurses Advisory Council

Join Nurses (NNAC) Around the Nation to fill gaps in patient care and prevention initiatives!
 

CFC / United Way Way       
        
  2009

 

Your United Way donation can be made directly to HFI and UW will still get credit. Give a check made out to HFI to your captain to get credit for UW and avoid paying administrative costs.

Win Win for HFI, CFC, UW, and You
 

Federal Employees Can Choose

Hepatitis Foundation International

Make HFI -
Your Charity Of Choice

Our CFC Agency Code:

        11842


 

 

  

 

 

 

 

Southeastern

 

Viral Hepatitis Summit

 

 Durham, North Carolina

 

 

Hepatitis Foundation International announces a 1 day

professional education and training Summit for health professionals

and others working with people who are affected by or infected with viral hepatitis, including: 

Text Box: ü     case managers
 
ü     others

 Text Box: ü     nurses
 
ü    counselors

 Text Box: ü     nurse practitioners                    
ü     physician assistants
 

 

 Registration information will follow soon

 


Good News! 

    The Hepatitis B and Hepatitis C bills have been combined in a
   
bipartisan bill – Viral Hepatitis and Liver Cancer Control and
    Prevention Act 2009 (HR 3974) and introduced in Congress by
    U.S. Representative Mike Honda (D-CA) and Charles Dent (R-PA)
    on October 29. This bill will expand education for patients and
    health care providers, increase access to hepatitis testing and
    live cancer screening, improve the capacity of health departments
    and support viral hepatitis prevention and education program
    across the nation. Click here to read the bill.  

 


Breaking News

  View "Give Your Liver A Break", an Emmy Awarded DVD on
   YouTube.
Click here

  Targeted Therapy Extends Survival for Liver Cancer
     Primary liver cell cancer is increasing in the U.S. Recent data
     suggest that the incidence rate has risen to approximately 5
     per 100,000 but the five-year survival remains suboptimal with
     8% overall survival in the United States. Thus there is a clear
     unmet need for more effective therapies.
Click here.

 

   Hepatitis C virus (HCV) progresses more rapidly after
   liver transplantation in African-Americans

       
Previous studies have shown that hepatitis C virus (HCV)
      progresses slower prior to
 liver transplantation in African
      Americans than in whites.
Click here.
 

   Twice Daily Oral Medication Shows Promise in Hepatitis C
      Researchers treated patients - both treatment naive and
      experienced patients - with a twice daily oral combination
      therapy of a nucleoside polymerase and protease inhibitor.
      The results were significant antiviral potency and sustained
      viral reductions.
Click here.
 

   Viral Load Predicts Outcome of Liver Transplant Recipients
   with HCV

     Viral load is an important factor and can predict the outcome
     of patients with hepatitis C virus (HCV) after liver
     transplantation, for both the development of the different
     types of recurrent HCV and patient survival.
Click here.
 

  Survival Lower in HCV-Infected Women after Liver Transplant

     Women undergoing liver transplant as a result of hepatitis C
     virus (HCV) infection show poorer long-term survival rates and
     more frequent failure of the donor liver, compared with male
     recipients.
Click here.

 

   New Biomarker Predicts Response to Hepatitis C Treatment
      Researchers at Duke University Medical Center have identified

    the first genetic marker that predicts response to hepatitis C

    treatments, and a single letter of DNA code appears to make a

    huge difference. Scientists say the biomarker not only predicts

    who is most likely to respond to treatment and who isn’t, but

    also may explain why there are such different response rates

    among racial and ethnic groups. Click here.

   

 


New CNE Course Announced


Articles of Interest                     

 

Impact of Lifestyles on Hepatitis C

    In HCV-infected patients, the top three predictors of liver

    related mortality were having higher body mass index (BMI),

    presence of insulin resistance (IR), and elevated serum

    cholesterol. Overall mortality in HCV patients was most linked

    to metabolic syndrome, higher BMI and hypertension.

    Click here for more information.

Telaprevir Effective in Treating Previously Failured Response

    
    Vertex’s telaprevir, an experimental drug for hepatitis C, is

    showing that it can cure about half of the patients who failed

    to respond to standard treatments. The study found that 51

    percent of patients who took telaprevir in combination with

    standard drugs for six months were cured and 52 percent were

    cured.

    Click here for more information.

 Phase 3 Albureron Trials Show Promising Results

   
The Phase 3 studies conducted by Human Genome Sciences,

    Inc, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated

    albinterferon alfa-2b vs. ginterferon alfa-2a, in combination

    with ribavirin, for use in the treatment of interferon-naive

    patients with chronic hepatitis C.

    Click here for more information.

Acetaminophen Painkillers to Carry Stronger Risk Warnings

      Pain relieving drugs containing Acetaminophen will be
     required to carry more explicit warning labels about the
     risk of liver damage and stomach bleeding especially for
     people who overdose on pain medicines or who drink three
     or more alcoholic drinks each day.

     Click here for more information.

 


 

News Notes

 

 

HBV Mutations May Predict Liver Cancer Risk

     A recent report published by the Journal of the National
     Cancer Institute states that certain mutations in the DNA of
     the hepatitis B virus are associated with the development of
     liver cancer and may be able to help determine which HBV
     patients are at increased risk.
      Click here for more information.

Sharing Insulin Pens a NO NO

 

    Individuals may be exposed to blood-borne pathogens that
    could cause diseases like hepatitis and HIV as a result of
    sharing insulin pens and insulin cartridges, which are only
    meant for single-patient use.  Although insulin pens may
    contain enough insulin for several rounds of injection by self
    administration, the FDA has issued a health alert warning
    against the sharing of devices, as they are only approved for
    use with one patient per device.  Even if the needles are
    changed between patients, it is not safe to share the insulin
    pens or insulin cartridges.  Blood-borne pathogens, such as
    HIV and the hepatitis viruses may contaminate the reservoir
    after the injection, before the needle is changed.


Hep A Vaccine Recommended for Parents Adopting Children

    U.S. citizens who expect to have close contact with an an an
    adopted child from countries with high rates of hepatitis A
    should be immunized if they have not been already, U.S.
    immunization advisers said on Wednesday.
    Click here for more information.


New Treatment Option for Unresectable Liver Cancer

    Nexavar is an oral multiple kinase inhibitor for the treatment
    of patients with unresectable hepatocellular carcinoma (HCC),
    the most common form of liver cancer, and patients with
    advanced renal cell carcinoma (RCC), the most common type
    of kidney cancer. Until now, patients with unresectable HCC
    have had limited treatment options.  Now, Nexavar offers a
    new treatment option with proven clinical benefits for
    unresectable HCC. Nexavar provides the latest information
    for the treatment of patients with unresectable HCC and
    patients with advanced RCC. It also provides links to
    comprehensive support programs to help patients with
    unresectable HCC or advanced RCC manage their therapy.


Changing Ailing Healthcare System

    Changing our ailing healthcare system includes promoting
    healthy lifestyle behaviors.  A Huge task at best.  The
    Hepatitis Foundation International (HFI) has a "leg up" on
    promoting healthy lifestyles in collaboration with many
    private and government agencies.  All Americans want to
    be healthy.
    Click here for more information.


Attention:  Men and Pregnant Women Taking Ribavirin
Registry Established for Potential Birth Defects

    The Registry enrolls pregnant women who have been
    inadvertently exposed to Ribavirin either directly (6 months
    before or during pregnancy) or indirectly (through her male
    sexual partner 6 months before or during pregnancy.

    Click here for more information


HFI’s Wellness Approach Included In CDC’s 2008 Top Five Evidence-Based Prevention Interventions.

    "Study to Reduce Intravenous Exposure" (STRIVE) was
    among the top five Evidence- Based HIV Prevention
    Interventions identified by the Centers for Disease Control
    and Prevention in 2008.
    Click here for release.

 

CDC Study: Failures to Follow Infection Practices Placed More Than 60,000 Patients at Risk for Hepatitis B and C_

     In the last decade, more than 60,000 patients in the United
    States were asked to get tested for hepatitis B virus (HBV)
    and hepatitis C virus (HCV) because health care personnel in
    settings outside hospitals failed to follow basic infection
    control practices, according to a new study done by the CDC.
    Click here for the full press release.

 

Research Advances
Make a Donation!  We need your support!

Your online purchases can benefit HFI at no cost to you!


Get updates on research advances and HFI's work in promoting liver wellness
Join Our Email List




***

HFI CEO Alerts Millions About Hepatitis


Click here to watch.


Donate to HFI

Hepatitis Foundation International (HFI) continues to work hard to provide up to date information and motivational messages for patients, educators, and the healthcare community.  We need your help to continue this important work!

Your donation to HFI can make a significant difference!





 

Hepatitis Foundation International


504 Blick Drive
Silver Spring, MD
20904-2901
USA

tel: 301-622-4200
800-891-0707
fax: 301-622-4702

 

     

 

the good we do  |  living with hepatitis  |  news & research  |  supportdonate  |  contact us  |  site map  |   home

NNAC  |  online learning center  |  subscribe to our newsletter   |   disclaimer  |  privacy

 

Hepatitis Foundation International
(800) 891-0707
HFI@comcast.net

©2003. All rights reserved.

 

 
web counter